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The serine 202 to phenylalanine substitution within
the cytoplasmic interdomain loop of Tet(C) greatly re-
duces tetracycline resistance and efflux activity (Sara-
ceni-Richards, C. A., and Levy, S. B. (2000) J. Biol. Chem.
275, 6101–6106). Second-site suppressor mutations were
identified following hydroxylamine and nitrosoguani-
dine mutagenesis. Three mutations, L11F in transmem-
brane 1 (TM1), A213T in the central interdomain loop,
and A270V in cytoplasmic loop 8–9, restored a wild type
level of resistance and an active efflux activity in Esch-
erichia coli cells bearing the mutant tet(C) gene. The Tet
S202F protein with the additional A270V mutation was
expressed in amounts comparable with the original mu-
tant, whereas L11F and A213T Tet(C) protein mutants
were overexpressed. Introduction of each single muta-
tion into the wild type tet(C) gene by site-directed mu-
tagenesis did not alter tetracycline resistance or efflux
activity. These secondary mutations may restore resist-
ance by promoting a conformational change in the pro-
tein to accommodate the S202F mutation. The data dem-
onstrate an interaction of the interdomain loop with
other distant regions of the protein and support a role
of the interdomain loop in mediating tetracycline
resistance.
One of the major bacterial protections against the growth
inhibitory action of tetracycline is exporting the drug out of the
cytoplasm, thus preventing its reaching the ribosome target
(2–4). Tet(B) and Tet(C) are cytoplasmic membrane proteins
belonging to the major facilitator superfamily (MFS) (5) that
maintain intracellular tetracycline concentrations below inhib-
itory levels via the energy-dependent antiport of H and a
divalent metal ion-tetracycline complex (6–8). Members of this
group, which includes uniporters, symporters, and antiporters,
share a common topology as well as regions of amino acid
sequence identity (9). The membrane topologies of Tet(B) and
Tet(C) have been studied by proteolysis (10, 11), chemical la-
beling (12–14), circular dichroism spectral analysis (15), and
gene fusion (16). Based on these studies and hydropathy anal-
ysis, the proteins are predicted to have 12 transmembrane
(TM)1 -helices divided into two equal intermembrane do-
mains,  and , by a large putative cytoplasmic loop designated
the interdomain region (Fig. 1) (11, 16, 17). Some resistance
can be obtained by cloning the two domains of the Tet protein
separately in the cell without the interdomain loop (18, 19).
Hybrid interclass Tet protein constructions and second-site
suppressor studies revealed that interactions of both domains
are required for Tet function (20, 21). Complete cysteine-scan-
ning mutagenesis of Tet(B) (22) has revealed that a total of 58
(14%) of the 401 amino acids contribute to the structure and/or
the function. Among them, 17, mostly glycine and proline, are
considered to be essential, whereas the other 41 affect the Tc
resistance phenotype mediated by Tet(B) only slightly. Four
mutations, D190C, E192C, S201C, and M210C, located within
the interdomain loop, caused greatly reduced tetracycline re-
sistance levels (8–32-fold) (22). A double frameshift within the
interdomain of Tet(A) changed its substrate specificity and
increased the efflux of minocycline and glycylcyclines (23). In
Tet(C), the interdomain mutation S202F leads to a 12-fold
increase in tetracycline susceptibility of the Escherichia coli
cells bearing the tet gene on a low copy number plasmid (1).
Moreover, the insertion of four residues increasing the length
of the Tet(C) interdomain loop increased Tc susceptibility (14).
Despite the poor conservation of the amino acid sequence, the
interdomain loop of tetracycline efflux proteins appears to be
important in the mediation of tetracycline resistance. This
study was designed to look for amino acid changes that re-
stored tetracycline efflux activity to a mutant strain having a
deleterious first mutation in the Tet(C) interdomain loop.
EXPERIMENTAL PROCEDURES
Materials—[3H]Tc (0.93 Ci/mmol) was purchased from PerkinElmer
Life Sciences. Restriction enzymes were obtained from New England
Biolabs (Beverly, MA). Pfu DNA polymerase, T4 DNA polymerase, and
T4 DNA ligase were purchased from Stratagene and Invitrogen. Anti-
biotics were obtained from Sigma, except for AHTc, which was prepared
in this laboratory. All other materials were reagent grade and obtained
from commercial sources.
Bacterial Strains, Plasmids, and Medium—Table I lists the bacterial
strains and plasmids used in this study. Escherichia coli cell cultures
were grown at 37 °C in Luria-Bertani (LB) broth (24) supplemented
with chloramphenicol (20 g/ml) and tetracycline (15 g/ml) as needed.
AHTc (15 ng/ml) was used as a gratuitous inducer of the Tet protein
where applicable (25).
Mutagenesis of Plasmid DNA—Mutagenesis in vitro was performed
with hydroxylamine, which specifically induces GC3 AT transitions by
deaminating the cytosine residues (26, 27). Approximately 3 g of
plasmid p202FCH prepared using the Qiagen Spin Mini preparation kit
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were incubated in 400 mM hydroxylamine, 50 mM potassium phosphate
buffer (pH6), and 100 mM EDTA in a 100-l volume for 40 min at 68 °C.
The entire volume was drop-dialyzed against sterile water for 1 h 30
min at room temperature on a type VS filter (0.025-m pore size)
(Millipore, Bedford, MA). The treated DNA was ethanol precipitated
and washed with 70% ethanol before being resuspended in sterile
water. Mutagenesis of p202FCH with MNNG was performed as de-
scribed previously in DH5 cells (28).
After both mutagenic events, 40 ng of plasmid DNA were introduced
by electroporation into DH5 electro-competent cells (24) using 0.2-cm
cuvettes and a Gene Pulser (Bio-Rad) at 200 ohms, 25 microfarads, and
25 kV/cm. To maximize the isolation of independent mutants, the entire
transformation mix (1 ml) was divided into 10 equal portions prior to
incubation and plating. Subsequently, transformants were selected on
plates containing chloramphenicol (20 g/ml) (for plasmid mainte-
nance) and tetracycline (15 g/ml). Tc-resistant mutants appeared usu-
ally after 24 h of incubation at 37 °C. Only one single colony per plate
was chosen for analysis to ensure that the mutants isolated were
generated in separate mutagenic events. Each colony was checked for
its tetracycline susceptibility by overnight liquid growth in LB broth
containing chloramphenicol and tetracycline (15 g/ml). The plasmids
from the Tc-resistant clones were extracted, and their copy numbers
were estimated by plasmid preparation on gels. Those plasmids whose
copy numbers were not increased were chosen to retransform DH5 to
assure that the Tc resistance observed was a plasmid-mediated muta-
tion in the tet gene.
Site-directed Mutagenesis—Site-directed mutagenesis of tet(C) on
plasmid pFS1 was performed by a two-stage PCR method adapted from
a PCR overlap method (29, 30). Two primers corresponding to the sense
and antisense sequence of the tet(C) gene were designed to incorporate
a restriction endonuclease site along with the desired mutation where
possible. The following sense primers were used: primer L11F, 5-CA-
ATGCGCTCATCGTAATATTCGGCACCGTC-3; primer A213T, 5-GG-
GGCATGACTATCGTCACCGCACTTATGACTGTC-3; and primer
A270V, 5-GCCTTCGTCACTGGTCCGGTCACCAAACGTTTCGGCGA-
G-3. Restriction endonuclease sites (SspI and BstEII in primers L11F
and A270V respectively), which were introduced to facilitate identifica-
tion of the desired mutants, are underlined.
Once the mutation was confirmed by sequencing and restriction
enzyme analysis, the 3.2-kb XhoI-XbaI-mutated Tet(C) determinant
was exchanged by cloning into the XhoI-BglII restriction sites of the
parental unmutagenized pCR2 plasmid. To facilitate the cloning of the
determinants, compatible cohesive ends were produced by blunt-ended
XbaI and BglII restriction sites with T4 DNA polymerase.
Nucleotide Sequencing—DNA sequencing was performed at the
Tufts University Core Facility using a ABI3100 Genetic Analyzer.
Determination of Tetracycline Susceptibility—AG100A cells harbor-
ing plasmids bearing wild type and tet(C)-mutated genes were grown in
the presence of chloramphenicol and AHTc to an A530 of 0.8. Cells were
swabbed for confluent growth onto a LB agar plate containing AHTc (15
ng/ml) before the application of the tetracycline E-test strips (gift from
AB Biodisk, Solna, Sweden). The minimum inhibitory concentration
was that amount of tetracycline showing an inhibition growth zone with
the E-test after 24 h of incubation at 37 °C.
Membrane Isolation and Western Blot Analysis—AG100A cells ex-
pressing various plasmid-specified Tet proteins were grown in the pres-
ence of AHTc (15 ng/ml) and rapidly chilled when they reached the late
logarithmic growth phase (A530  0.8). Following centrifugation, cells
were resuspended in 20 mM Tris-HCl (pH8), 2 mM MgCl2, 1 mM EDTA,
and 30 g/ml lysozyme (A530 of 100) prior to sonication (Branson Soni-
fier 250, Branson Ultrasonics Corporations, Danbury, CT). Membranes
were collected by centrifugation at 60 000  g for 1 h at 4 °C. Tet
proteins were solubilized by incubating the membranes in 20 mM Tris-
HCl (pH8), 150 mM NaCl, 10% glycerol, and 1.5% dodecylmaltoside at
4 °C for 1 h (A530  250). Membranes were removed by sedimentation
for 30 min at 15,000  g in 1.5-ml Eppendorf tubes, and extracts were
stored at 80 °C. Before electrophoresis, extracted proteins were incu-
bated in reducing sample buffer (24) for 20 min at room temperature.
Proteins were separated by electrophoresis in a 10% SDS-polyacryl-
amide gel (24) using a Miniprotein II gel apparatus (Bio-Rad) and then
transferred to a PolyScreen polyvinylidene difluoride transfer mem-
brane (PerkinElmer Life Sciences) per the manufacturer’s recommen-
dations. Immunological detection was carried out with polyclonal anti-
bodies directed against the 14 carboxyl-terminal (Ct) amino acids of
Tet(B) (anti-Ct antibody, kindly provided by A. Yamaguchi) (31). The
antigen-antibody complexes were detected with horseradish peroxidase
coupled to the anti-rabbit IgG (New England Biolabs). Blots were de-
veloped with the Renaissance Western blot chemiluminescence reagent
plus kit (PerkinElmer Life Sciences). The band intensities of each
Tet(C) derivative were determined using NIH Image 1.6.2 free
software (www.scioncorp.com).
Tetracycline Accumulation Assays—The measurement of [3H]Tc up-
take by intact AG100A cells containing mutant plasmids was adapted
from previous works (1, 4). Bacteria grown to exponential phase in LB
broth containing AHTc were pelleted by centrifugation (15,000  g for
5 min), washed in 10 mM Tris-HCl (pH8) buffer, and suspended in 50
mM potassium phosphate buffer (pH 6.6), 10 mM MgSO4, and 0.2%
glucose (A530  4). After 3 min of preincubation, [
3H]Tc was added to
270 l of cell suspension with shaking at 30 °C in a water bath, yielding
a final tetracycline concentration of 1 M. At various intervals, 50 l of
the suspension were removed, mixed with 10 ml of 0.1 M potassium
phosphate buffer (pH6.6) and 0.1 M LiCl at 20 °C, and filtered through
a Metricel® membrane filter (pore size, 0.45 m). The filters were
washed with 4 ml of the same buffer and dried before the radioactivity
was measured with a liquid scintillation counter. The protonophore
CCCP was added to a final concentration of 100 M at 18 min to
deenergize the cells. Each strain was assayed in triplicate in three
separate experiments. The value at each time point deviated 8%.
RESULTS
Characterization of Tc-resistant Mutants—Following chemi-
cal treatments with hydroxylamine or nitrosoguanidine, a total
of nine individual Tc-resistant mutants were isolated. The se-
quencing of the promoter and coding region of tet(C) confirmed
a single base change in each clone leading to three different
types of amino acid substitution (Fig. 1). Among all the clones
identified, no reversion to the wild type codon was seen. In six
different clones obtained with both methods (five hydroxyla-
mine and one MNNG), a CTC3 TTC mutation was observed at
position 11, which led to the substitution of the leucine by a
phenylalanine residue. The leucine 11 is conserved among all
classes and is predicted to be within the TM1 (32). In two
additional MNNG mutants, a GCC3 ACC transition resulted
in a change from alanine 213 to a threonine residue. Based on
the current topological model of Tet(C) developed by Varela et
al. (33) and alignment with the Tet(B) model (17), the location
of alanine 213 is predicted to be within the central interdomain
loop connecting the  and  domains. This alanine residue is
also conserved in the class D Tet protein that shares 78%
homology with the class C protein. Finally, one last mutant,
resulting from mutagenesis with MNNG, contained a GCC to
GTC change that resulted in the substitution of valine for the
alanine at position 270. The alanine was predicted to be in the
cytoplasmic loop linking TM8 and TM9 (13, 34).
AG100A cells devoid of the AcrAB pump were highly suscep-
tible to tetracycline (minimum inhibitory concentration  0.3
g/ml) (Table II). When complemented with a low copy number
plasmid bearing the wild type tet(C), the minimum inhibitory
TABLE I
Bacterial strains and plasmids
Relevant genotype Ref.
Strain
DH5 supE44 lacU169(80 lacZ M15)
hsdR17 recA1 endA1 gyrA96
thi-1 relA1
40
AG100A acrAB::Tn903 kanr argE3 thi-1
rpsL xyl mtl (gal-uvrB) supE44
41
Plasmid
pCR2 Cmr, P15A ori, wild type Tet (C)
determinanta
1
p202FCH pCR2 carrying mutant S202F-Tet
(C) determinanta
1
pMCL210 Cmr, P15A ori, lacZ cloning vector 42
pFS1 pMCL210 carrying the 3.2kb Tet
(C) determinanta from pCR2
This study
a Tet (C) determinant was genetically constructed to express the last
14 amino acids of Tet(B) (instead of its last six ones). This change
allowed detection of the class C protein with antibody raised against the
region of Tet(B) (1).
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concentration in AG100A rose to 16 g/ml. The presence of the
single mutation S202F in Tet(C) decreased the tetracycline
resistance by 4-fold to 4 g/ml. Wild type Tc resistance was
restored by each of the secondary mutations, A213T/S202F and
A270V/S202F, and an even higher level of resistance was pro-
vided with the L11F/S202F mutation (24 g/ml). Subsequently,
each mutation was introduced by site-directed mutagenesis
into Tet(C) specified by the plasmid pFS1. These mutations
alone had no effect on the level of Tc resistance and could,
therefore, be considered as not essential for Tet(C) activity
(Table II). Thus, the secondary suppressor mutations are nec-
essary to suppress the effect of the first mutation but are not by
themselves critical for Tet protein function.
Western Blot Analysis of Tet Protein Expression—Western
blot analysis of the Tet protein was performed using the anti-Ct
antibody. The inactivating mutation S202F slightly reduced
(10%) the level of protein production (Fig. 2) but confirmed the
belief that the low level of resistance was not attributable to a
poor expression of the protein. The double mutant protein
A270V/S202F was expressed in quantities comparable with the
parental S202F mutant (Fig. 2A). On the other hand, the pro-
tein with the secondary L11F or A213T mutations showed
increased amounts in the cells in which they were expressed
(Fig. 2A). The introduction of each single suppressor mutation
into the wild type determinant did not change protein expres-
sion or mobility in a detectable manner (Fig. 2B).
Analysis of Tetracycline Efflux Activity—Tc resistance is
characterized by a reduction in the cellular accumulation of Tc
brought about by a proton motive force-dependent efflux (4, 35).
We measured the energy-dependent Tc efflux as the relative
uptake of [3H]Tc before and after deenergization of the cells
with the protonophore CCCP. AG100A, devoid of the AcrAB
pump and any Tet protein, accumulated 38 pmol of [3H]Tc in 18
min (Fig. 3A). The addition of 100 M CCCP resulted in a loss
of Tc from the cell, which was attributed to the dissipation of
the proton gradient across the membrane upon which Tc up-
take is dependent (7). However, when AG100A expressed the
wild type Tet(C), it showed a lower uptake of [3H]Tc (13.9 pmol)
(Fig. 3A), which increased when cells were treated with CCCP.
The strain carrying the S202F mutation accumulated nearly
21.9 pmol of [3H]Tc in 18 min but was unaffected by CCCP
addition (Fig. 3A). This lack of effect of CCCP was observed
previously for some low level Tet protein mutants (36).
TABLE II
Tetracycline susceptibility of AG100A cells bearing plasmids
expressing the wild type or mutant Tet(C) proteins
The susceptibilities are expressed as minimal inhibitory concentra-
tion revealed by E-test on AHTc-induced AG100A cells. Representative
of experiments performed three times.











FIG. 1. Membrane topology of the Tet(C) protein. Transmembrane -helices of the protein are indicated in the rectangles numbered 1–12.
Residues recognized by an antibody raised against the class B Tet protein are shown in boldface at the carboxyl-terminal end. Serine 202 is within
the interdomain cytoplasmic loop and is designated by a black square. Circled letters locate secondary suppressor mutations of S202F. The I helix
is boxed and indicated by an arrow.
FIG. 2. Western blot analysis of wild type and mutated Tet(C)
proteins. Extracted membrane proteins (2.5 g) of AG100A cells ex-
pressing various Tet proteins were transferred and probed with anti-Ct
antibody. A, wild type Tet(C) and secondary suppressor mutations of
S202F. B, wild type Tet(C) and single mutations. Quantities of mutant
Tet(C) proteins are represented as a percentage of the wild type protein
assigned a value of 100% within the same blot. Representative of
experiments performed in triplicate.
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All three suppressor mutations restored an active Tc efflux
comparable with the wild type (Fig. 3B). Modification of the
wild-type Tet(C) protein with each single suppressor mutation
revealed no distinguishable change in the efflux activity as
compared with the wild type Tet protein (Fig. 3C).
DISCUSSION
The cytoplasmic interdomain loop of Tet proteins has been
considered to be only a means of connecting two active domain
halves, because the loop is so divergent in its sequence among
various tetracycline resistance determinants whose two  and
 domains are much more similar (37). Moreover, some resist-
ance can be obtained by cloning the two domains of the Tet
protein separately in the cell without the interdomain loop (18,
19). However, previous studies pointed out that a double frame-
shift mutation in the interdomain loop of TetA modified the
substrate specificity of the protein (23) and that local muta-
tions within the loop greatly reduced the Tc resistance pheno-
type (1, 17, 22).
We have isolated and characterized three different types of
amino acid substitution suppressor mutations arising in nine
independently isolated mutants that restore the tetracycline
efflux function in Tet(C) with the S202F mutation in the inter-
domain loop. One secondary suppressor mutation, L11F, would
increase the bulkiness of the side chain at this position.
Leucine 11, predicted to be relatively close to the cytoplasmic
side of the membrane within TM1, is conserved among all of
the classes of Gram-negative Tet proteins that have been iden-
tified to date. Its change suggests an interaction of TM1 with
the interdomain loop. According to Tamura et al. (22), TM1 is a
partly amphiphilic helix with several residues facing the water
channel built by portions of TM2, TM4, TM5, TM7, TM8,
TM10, and TM11. It is therefore possible that this secondary
suppressor mutation modifies the structure of TM1 and re-
stores a wild type tetracycline resistance phenotype by correct-
ing the active site altered by the S202F mutation.
A second suppressor mutation, A213T in the cytoplasmic
loop (Fig. 1), slightly increases the size of the side chain while
introducing a hydrophilic residue. Prediction deduced from hy-
dropathy plots has shown an additional cytoplasmic  helix-
(I) located within the interdomain loop (Fig. 1), between ser-
ine 202 and arginine 207. A similar feature of 13 amino acids
has been pointed out in the three-dimensional crystallographic
structure of the efflux transporter AcrB, and it has been pos-
tulated that the I helix is attached to the cytoplasmic mem-
brane surface (38). This feature may also be true for Tet(C).
The predicted position of A213T near the cytoplasmic surface of
the protein could improve binding of the mutated putative I
structure to the membrane. Of note, the mutation led to a
3–4-fold higher amount of the protein without showing a
greater efflux activity, suggesting that the protein itself is still
not completely wild type in function. Although the reason for
the increased protein is not yet clear, the single A213T change
in Tet(C) did not alter protein amount or function (Figs. 2 and
3). Thus, it appears that the combined interdomain mutations
(S202F  A213T) add stability to the protein embedded in the
membrane. Analogously, the length and nature of the residues
of the interdomain loop of LacY, a member of the major facili-
tator superfamily, affected the insertion and stability of the
protein in the membrane (39). Hydrophilic residues within the
interdomain loop of LacY are required to permit a temporal
delay for the insertion of both domains.
A third suppressor mutation, A270V, predicted to be within
the cytoplasmic loop between TM8 and TM9, restored an effi-
cient tetracycline resistance phenotype and efflux activity
without modifying the level of Tet production. The position on
the same side of the protein suggests that the loop 8-9 interacts
somehow with the interdomain loop and that the A270V mu-
tation improves the interaction in the presence of the
S202F mutation.
The loss of tetracycline efflux activity of the mutant S202F
Tet(C) could be interpreted as a modification of the conforma-
tion of the I helix that could perturb the correct positioning of
the active site involving the interaction between  and  do-
mains. In Tet(B), substitution of the homologous serine 202 by
a cysteine residue also led to an increase in tetracycline sus-
ceptibility (17). Interestingly, cysteine-scanning mutagenesis
analysis revealed no labeling of S201C with [14C]N-ethylmale-
imide. This finding suggests that the serine, while in the water-
exposed loop, is oriented into the protein interior as a mem-
brane-interactive residue (17).
The introduction of the single mutations L11F, A213T, and
A270V into Tet(C) did not produce any detectable change in the
wild type Tet(C) activity or expression. This finding suggests
that serine 202 plays a capital but not essential role in the
functional activity of Tet(C). In this case, any conformational
modification brought by each mutation is not sufficient to de-
FIG. 3. Accumulation of [3H]Tc by E. coli AG100A cells expressing wild type and mutant Tet proteins. Accumulation was measured
as pmol of [3H]Tc in intact exponential phase cells. The arrows indicate CCCP (100 M) addition. Representative of experiments performed
three times.
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stroy the interaction of serine 202 with other specific portion(s)
of the protein. Although the precise role of the cytoplasmic
interdomain loop in tetracycline resistance is not clear, it
should be reevaluated as being more than a simple linker
between the  and  domains because it affects Tet protein-
specified tetracycline resistance.
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